Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Plaque Psoriasis
Interventions
DRUG

ME3183

ME3183 capsule

DRUG

Placebo

Placebo capsule

Trial Locations (27)

14623

Skin Search of Rochester, Inc., Rochester

33144

International Dermatology Research, INC, Miami

37215

Tennessee Clinical Research Center, Nashville

42303

Owensboro Dermatology Associates, Owensboro

47715

Qualmedica Research, LLC, Evansville

70605

Shondra L. Smith, MD Dermatology & Advanced Aesthetics, Lake Charles

72758

Northwest Arkansas Clinical Trials Center, Rogers

75230

Dermatology Treatment and Research Center, Dallas

77004

Center for Clinical Studies LTD, LLP, Houston

77433

Studies in Dermatology, LLC, Cypress

78229

Dermatology Clinical Research Center of San Antonio, San Antonio

80210

Colorado Medical Research Center, Inc., Denver

90033

University of Southern California, Los Angeles

99202

Premier Clinical Research, Spokane

T5J 3S9

Laser Rejuvenation Clinics Edmonton D.T. Inc, Edmonton

K9A 0Z4

SKiN Health, Cobourg

P3A 1W8

Sudbury Skin Clinique, Greater Sudbury

L8N 1Y2

Dermatrials Research Inc., Hamilton

N6H 5L5

DermEffects, London

L3P 1X3

Lynderm Research Inc., Markham

L4Y 4C5

DermEdge Research, Mississauga

K2C 3N2

Dermatology Ottawa Research Centre, Ottawa

L4B 1A5

The Centre for Dermatology, Richmond Hill

M3H 5Y8

Toronto Research Centre, Toronto

N2J 1C4

K. Papp Clinical Research, Waterloo

H3H 1V4

Dr. David Gratton Dermatologue Inc., Montreal

S7K 2C1

Skinsense Medical Research, Saskatoon

Sponsors
All Listed Sponsors
lead

Meiji Pharma USA Inc.

INDUSTRY